Treatment
Share your love
OSA 2024 Winners Highlight Innovations in Ophthalmology
VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, handed the prestigious Ophthalmology Star Awards 2024 (OSA) to its owners during the Satellite Symposium at the ESCRS 2024 Congress in Barcelona. The awards, which were personally presented to…
Reducing the Carbon Footprint of Intravitreal Injections
Adopting specific treatment protocols, minimizing travel for patients and staff, and reducing unnecessary use of personal protective equipment (PPE) can significantly decrease the carbon footprint of intravitreal injections. This topic was discussed in detail by Redmer van Leeuwen, MD, PhD,…
Study: Aromatherapy Eases Post-Surgery Anxiety and Pain
A recent study suggests that aromatherapy may effectively reduce postoperative anxiety and pain in patients undergoing oculoplastic procedures under monitored anesthetic sedation. Published in Ophthalmic Plastic and Reconstructive Surgery, this randomized controlled trial highlights the potential of aromatherapy as an…
Study Links Socioeconomics to Severe Retinal Detachment
A recent study indicates that patients living in socioeconomically deprived neighborhoods are more likely to present with severe rhegmatogenous retinal detachment (RRD), a serious eye condition that can lead to vision loss if not treated promptly. Adverse social determinants of…
De-escalated Chemo Effective for High-Risk Retinoblastoma
A recent study reveals that a shortened adjuvant chemotherapy regimen offers similar efficacy and improved safety for infants with unilateral pathologic high-risk retinoblastoma. Results showed enhanced five-year disease-free survival (DFS) among infants receiving three cycles of chemotherapy compared to those…
Hidden Visual Deficits in Mild TBI Uncovered
A groundbreaking study led by Vanderbilt University Medical Center has unveiled subtle changes in the visual pathways of individuals with chronic mild traumatic brain injury (TBI). These findings highlight structural and functional deficits, even when standard eye examinations reveal no…
Neuronal Circuit Model Unlocks Eye Movement Insights
A groundbreaking study by researchers at Weill Cornell Medicine and collaborators has unveiled how neuronal circuits in the brainstem guide eye movement, offering potential advancements in the treatment of eye movement disorders. Using week-old zebrafish, the team explored how connections…
Cambium Bio Raises Funds for Dry Eye Trials
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling…
Galimedix Starts Phase 1 Trial for Oral GAL-101
Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for oral GAL-101, an innovative amyloid beta (Aβ) aggregation modulator. The study aims to assess the therapy’s safety, tolerability, and pharmacokinetics, marking a significant step…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…